Terril Brothers Inc. decreased its position in Biogen Inc (NASDAQ:BIIB) by 0.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 57,568 shares of the biotechnology company’s stock after selling 347 shares during the period. Biogen makes up 5.6% of Terril Brothers Inc.’s portfolio, making the stock its 8th largest position. Terril Brothers Inc.’s holdings in Biogen were worth $18,339,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in BIIB. Assenagon Asset Management S.A. acquired a new position in Biogen in the 3rd quarter worth $123,494,000. Cambridge Investment Research Advisors Inc. boosted its stake in Biogen by 9.6% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 5,948 shares of the biotechnology company’s stock worth $1,862,000 after purchasing an additional 520 shares during the period. Cubist Systematic Strategies LLC boosted its stake in Biogen by 151.3% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 10,646 shares of the biotechnology company’s stock worth $3,333,000 after purchasing an additional 6,409 shares during the period. IFP Advisors Inc boosted its stake in Biogen by 47.1% in the 3rd quarter. IFP Advisors Inc now owns 3,330 shares of the biotechnology company’s stock worth $1,043,000 after purchasing an additional 1,066 shares during the period. Finally, Bainco International Investors boosted its stake in Biogen by 4.4% in the 3rd quarter. Bainco International Investors now owns 18,671 shares of the biotechnology company’s stock worth $5,846,000 after purchasing an additional 790 shares during the period. 88.18% of the stock is owned by institutional investors.

In related news, Director Alexander J. Denner purchased 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 29th. The shares were acquired at an average price of $317.36 per share, for a total transaction of $9,520,800.00. Following the purchase, the director now owns 10,029 shares in the company, valued at $3,182,803.44. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Robert W. Pangia sold 5,832 shares of the company’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $329.65, for a total transaction of $1,922,518.80. Following the completion of the transaction, the director now owns 23,539 shares in the company, valued at approximately $7,759,631.35. The disclosure for this sale can be found here. Over the last ninety days, insiders bought 31,560 shares of company stock worth $10,020,858. 0.25% of the stock is owned by insiders.

A number of equities analysts recently weighed in on the stock. Royal Bank of Canada reaffirmed a “hold” rating and issued a $321.00 target price on shares of Biogen in a research note on Tuesday, December 5th. Nomura upped their target price on shares of Biogen from $355.00 to $420.00 and gave the stock a “buy” rating in a research note on Saturday, December 30th. BidaskClub raised shares of Biogen from a “hold” rating to a “buy” rating in a research note on Friday, January 5th. Mizuho set a $400.00 target price on shares of Biogen and gave the stock a “buy” rating in a research note on Monday, November 13th. Finally, Morgan Stanley raised shares of Biogen from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $311.00 to $375.00 in a research note on Thursday, October 5th. Nine research analysts have rated the stock with a hold rating, twenty-two have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $354.96.

Shares of Biogen Inc (NASDAQ BIIB) traded up $5.23 during mid-day trading on Tuesday, hitting $347.64. 1,195,200 shares of the stock were exchanged, compared to its average volume of 1,217,071. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.90 and a current ratio of 2.19. The company has a market cap of $73,330.00, a PE ratio of 21.31, a price-to-earnings-growth ratio of 1.94 and a beta of 0.73. Biogen Inc has a 12 month low of $244.28 and a 12 month high of $348.84.

Biogen (NASDAQ:BIIB) last issued its earnings results on Tuesday, October 24th. The biotechnology company reported $6.31 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $5.70 by $0.61. The company had revenue of $3.08 billion for the quarter, compared to analysts’ expectations of $3.05 billion. Biogen had a net margin of 29.44% and a return on equity of 38.51%. Biogen’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.19 EPS. research analysts anticipate that Biogen Inc will post 22 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://theolympiareport.com/2018/01/23/terril-brothers-inc-has-18-34-million-stake-in-biogen-inc-biib.html.

About Biogen

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc (NASDAQ:BIIB).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.